A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.

Autor: Mannion, Jonathan1 (AUTHOR), Gifford, Valentina1 (AUTHOR), Bellenie, Benjamin1,2 (AUTHOR), Fernando, Winnie1 (AUTHOR), Ramos Garcia, Laura1 (AUTHOR), Wilson, Rebecca1 (AUTHOR), John, Sidonie Wicky1 (AUTHOR), Udainiya, Savita1 (AUTHOR), Patin, Emmanuel C.3 (AUTHOR), Tiu, Crescens1 (AUTHOR), Smith, Angel1 (AUTHOR), Goicoechea, Maria1 (AUTHOR), Craxton, Andrew4 (AUTHOR), Moraes de Vasconcelos, Nathalia1 (AUTHOR), Guppy, Naomi1 (AUTHOR), Cheung, Kwai-Ming J.2 (AUTHOR), Cundy, Nicholas J.2 (AUTHOR), Pierrat, Olivier2 (AUTHOR), Brennan, Alfie2 (AUTHOR), Roumeliotis, Theodoros I.5 (AUTHOR)
Zdroj: Immunity (10747613). Jul2024, Vol. 57 Issue 7, p1514-1514. 1p.
Databáze: Academic Search Ultimate